227 related articles for article (PubMed ID: 38241301)
21. Higher body mass index may be a predictor of extrathyroidal extension in patients with papillary thyroid microcarcinoma.
Choi JS; Kim EK; Moon HJ; Kwak JY
Endocrine; 2015 Feb; 48(1):264-71. PubMed ID: 24858734
[TBL] [Abstract][Full Text] [Related]
22. Analysis of differential BRAF(V600E) mutational status in high aggressive papillary thyroid microcarcinoma.
Lee X; Gao M; Ji Y; Yu Y; Feng Y; Li Y; Zhang Y; Cheng W; Zhao W
Ann Surg Oncol; 2009 Feb; 16(2):240-5. PubMed ID: 19034577
[TBL] [Abstract][Full Text] [Related]
23. The BRAFT1799A mutation is not associated with occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma.
Wan HF; Zhang B; Yan DG; Xu ZG
Asian Pac J Cancer Prev; 2015; 16(7):2947-51. PubMed ID: 25854387
[TBL] [Abstract][Full Text] [Related]
24. Which papillary thyroid microcarcinoma should be treated as "true cancer" and which as "precancer"?
Kaliszewski K; Diakowska D; Wojtczak B; Forkasiewicz Z; Pupka D; Nowak Ł; Rudnicki J
World J Surg Oncol; 2019 May; 17(1):91. PubMed ID: 31146753
[TBL] [Abstract][Full Text] [Related]
25. BRAF Status in Papillary Microcarcinomas of the Thyroid Gland: a Brief Review.
Ieni A; Vita R; Cardia R; Giuffré G; Benvenga S; Tuccari G
Curr Mol Med; 2019; 19(9):665-672. PubMed ID: 31625469
[TBL] [Abstract][Full Text] [Related]
26. Preoperative BRAF mutation is predictive of occult contralateral carcinoma in patients with unilateral papillary thyroid microcarcinoma.
Zhou YL; Zhang W; Gao EL; Dai XX; Yang H; Zhang XH; Wang OC
Asian Pac J Cancer Prev; 2012; 13(4):1267-72. PubMed ID: 22799316
[TBL] [Abstract][Full Text] [Related]
27. Endoplasmic reticulum aminopeptidase 2 is highly expressed in papillary thyroid microcarcinoma with cervical lymph node metastasis.
Kim WY; Lee JB; Kim HY; Woo SU; Son GS; Bae JW
J Cancer Res Ther; 2015; 11(2):443-6. PubMed ID: 26148615
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic predictors of central lymph node metastases in clinical node-negative papillary thyroid microcarcinoma: a systematic review and meta-analysis.
Wen X; Jin Q; Cen X; Qiu M; Wu Z
World J Surg Oncol; 2022 Apr; 20(1):106. PubMed ID: 35365171
[TBL] [Abstract][Full Text] [Related]
29. Mutational profile of papillary thyroid microcarcinoma with extensive lymph node metastasis.
Jeon MJ; Chun SM; Lee JY; Choi KW; Kim D; Kim TY; Jang SJ; Kim WB; Shong YK; Song DE; Kim WG
Endocrine; 2019 Apr; 64(1):130-138. PubMed ID: 30645724
[TBL] [Abstract][Full Text] [Related]
30. Extent of Surgery and the Prognosis of Unilateral Papillary Thyroid Microcarcinoma.
Zhao H; Cui L
Front Endocrinol (Lausanne); 2021; 12():655608. PubMed ID: 34220708
[TBL] [Abstract][Full Text] [Related]
31. Management of cN0 papillary thyroid microcarcinoma patients according to risk-scoring model for central lymph node metastasis and predictors of recurrence.
Feng JW; Ye J; Wu WX; Qu Z; Qin AC; Jiang Y
J Endocrinol Invest; 2020 Dec; 43(12):1807-1817. PubMed ID: 32557354
[TBL] [Abstract][Full Text] [Related]
32. Predictive Factors of Lymph Node Metastasis in Patients With Papillary Microcarcinoma of the Thyroid: Retrospective Analysis on 293 Cases.
Medas F; Canu GL; Cappellacci F; Boi F; Lai ML; Erdas E; Calò PG
Front Endocrinol (Lausanne); 2020; 11():551. PubMed ID: 32982963
[No Abstract] [Full Text] [Related]
33. Identification of risk factors of central lymph node metastasis and evaluation of the effect of prophylactic central neck dissection on migration of staging and risk stratification in patients with clinically node-negative papillary thyroid microcarcinoma.
Yuan J; Li J; Chen X; Lin X; Du J; Zhao G; Chen Z; Wu Z
Bull Cancer; 2017 Jun; 104(6):516-523. PubMed ID: 28476312
[TBL] [Abstract][Full Text] [Related]
34. Clinicopathological, immunohistochemical factors and recurrence associated with extrathyroidal extension in papillary thyroid microcarcinoma.
Kim WY; Kim HY; Son GS; Bae JW; Lee JB
J Cancer Res Ther; 2014; 10(1):50-5. PubMed ID: 24762486
[TBL] [Abstract][Full Text] [Related]
35. Papillary thyroid microcarcinomas that metastasize to lymph nodes.
Dirikoc A; Tam AA; Ince N; Ozdemir D; Topaloglu O; Alkan A; Yazgan AK; Ersoy R; Cakir B
Am J Otolaryngol; 2021; 42(5):103023. PubMed ID: 33838358
[TBL] [Abstract][Full Text] [Related]
36. Nomogram for Preoperative Estimation of Cervical Lymph Node Metastasis Risk in Papillary Thyroid Microcarcinoma.
Sun J; Jiang Q; Wang X; Liu W; Wang X
Front Endocrinol (Lausanne); 2021; 12():613974. PubMed ID: 33868164
[TBL] [Abstract][Full Text] [Related]
37. Papillary thyroid microcarcinoma with minimal extrathyroidal extension. Is its course so indolent that it requires a less aggressive treatment?
Ruiz Pardo J; Ríos Zambudio A; Rodríguez González JM; Paredes Quiles M; Soriano Giménez V; Oviedo Ramírez MI; Hernández Martínez AM; Parrilla Paricio P
Rev Clin Esp (Barc); 2021 Mar; 221(3):131-138. PubMed ID: 33998460
[TBL] [Abstract][Full Text] [Related]
38. Risk factors for neck nodal metastasis in papillary thyroid microcarcinoma: a study of 1066 patients.
Zhang L; Wei WJ; Ji QH; Zhu YX; Wang ZY; Wang Y; Huang CP; Shen Q; Li DS; Wu Y
J Clin Endocrinol Metab; 2012 Apr; 97(4):1250-7. PubMed ID: 22319042
[TBL] [Abstract][Full Text] [Related]
39. Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation.
Ito Y; Miyauchi A; Kihara M; Higashiyama T; Kobayashi K; Miya A
Thyroid; 2014 Jan; 24(1):27-34. PubMed ID: 24001104
[TBL] [Abstract][Full Text] [Related]
40. [Retrospective comparison of screening criteria for active surveillance for papillary thyroid microcarcinoma].
Qian K; Sun TQ; Guo K; Zheng XK; Li DS; Wei WW; Wu Y; Ji QH; Wang ZY
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2017 Jun; 52(6):430-434. PubMed ID: 28635215
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
